Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Benazepril hydrochloride
Drug ID BADD_D00228
Description Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Indications and Usage Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].
Marketing Status approved; investigational
ATC Code C09AA07
DrugBank ID DB00542
KEGG ID D00620
MeSH ID C044946
PubChem ID 5362123
TTD Drug ID D0U3EC
NDC Product Code 51927-0104; 65862-116; 23155-749; 42291-162; 43063-679; 50090-3243; 51655-388; 53746-751; 63629-8035; 70771-1149; 65129-2021; 23155-750; 51407-463; 51655-065; 53746-752; 53746-754; 60760-352; 63187-500; 68788-7845; 70771-1150; 13612-0002; 65862-117; 71052-173; 23155-752; 51655-202; 65162-753; 68071-1026; 71205-320; 55154-4344; 63187-499; 70934-608; 71335-0011; 72162-1816; 30698-449; 43063-677; 50090-5751; 55154-4343; 65162-754; 68788-9313; 68788-9327; 70518-2125; 71335-1086; 50090-3775; 50268-109; 51407-465; 51655-617; 61919-756; 65162-751; 68071-2929; 70518-3171; 70518-3528; 71335-0457; 71335-0854; 42291-163; 43547-338; 50090-3359; 50268-110; 51407-462; 51407-464; 60760-351; 63187-393; 63187-906; 68788-6889; 70771-1148; 71335-1365; 44139-0026; 43547-336; 50090-5750; 53002-1233; 65862-118; 68788-6957; 70518-1640; 70518-3172; 70771-1151; 70934-483; 71335-0267; 71335-1299; 23155-751; 42291-161; 51655-755; 53746-753; 70934-983; 72189-110; 15308-0900; 17404-0016; 51927-0105; 58159-086; 65862-346; 30698-448; 43547-337; 50268-112; 53002-1248; 55700-291; 65162-752; 68071-1770; 70518-3074; 71205-244; 71335-0078; 22568-1136; 51927-0036; 64220-145; 30698-450; 43063-748; 43547-335; 50268-111; 51655-066
UNII N1SN99T69T
Synonyms benazepril | benazapril | benzazepril | Labopal | Lotensin | Cibacène | Cibacen | Briem | benazepril hydrochloride | CGS-14824-A | CGS-14824A
Chemical Information
Molecular Formula C24H29ClN2O5
CAS Registry Number 86541-74-4
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001---
Alopecia23.02.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Arrhythmia02.03.02.001---
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001---
Asthma10.01.03.010; 22.03.01.002---
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006---
Bronchitis11.01.09.001; 22.07.01.001--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Constipation07.02.02.001--
Coordination abnormal17.02.02.004---
Cough22.02.03.001--
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.008---
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages